Get the Stockscreener App
1.40
3.45%
-0.05
After Hours:
1.41
0.01
+0.71%
Gri Bio Inc stock is traded at $1.40, with a volume of 23,046.
It is down -3.45% in the last 24 hours and down -23.08% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$1.45
Open:
$1.44
24h Volume:
23,046
Relative Volume:
0.37
Market Cap:
$2.48M
Revenue:
-
Net Income/Loss:
$-10.91M
P/E Ratio:
-0.0176
EPS:
-79.5513
Net Cash Flow:
$-12.14M
1W Performance:
-4.76%
1M Performance:
-23.08%
6M Performance:
-73.68%
1Y Performance:
-97.49%
1-Day Range:
$1.39
$1.47
1-Week Range:
$1.39
$1.57
52-Week Range:
$1.39
$80.36
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.40 | 2.57M | 0 | -10.91M | -12.14M | -79.55 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
GRI Bio Inc (GRI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GRI|GRI Bio Inc|Price:1.450|Chg%:-0.050 - TradingKey
GRI Bio Inc (GRI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gri Bio, Inc. (GRI) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
TradingKey - TradingKey
GRI Bio, Inc. Revenue Breakdown – NASDAQ:GRI - TradingView
GRI Bio Inc (GRI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GRI Bio Inc (GRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
CHGA Stock Price and Chart — NASDAQ:CHGA - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates by 76%, Stock Rises 2.6% Amid Strategic Progress - Bölüm Sonu Canavarı
Price to earnings forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Revenue AbsentSubscription Growth Report - dars.gov.et
GRI Bio Inc. (GRI) Declines Over 8%, Approaching Critical Support at $1.73Liquidity Order Flow - dars.gov.et
GRI Q1 2026 Earnings: EPS Misses Estimates by 76%, Shares Slide 8%Mid-Term Outlook - dars.gov.et
Price to sales forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to revenue forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates by over 76% as Pre-Revenue Biotech Continues Development - dars.gov.et
Enterprise value to EBIT forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
Price to earnings forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to EBIT forward of GRI Bio, Inc. – BOATS:GRI - TradingView
Enterprise value to EBITDA forward of GRI Bio, Inc. – NASDAQ:GRI - TradingView
GRI Q1 2026 Earnings: EPS Miss Widens Losses as Pre-Revenue Biotech Stock RalliesProfit Margin Analysis - DonanımHaber
ADTX Stock Price and Chart — OTC:ADTX - TradingView
GRI Bio, Inc. Actuals & Estimates (NASDAQ:GRI) - TradingView
GRI Forecast — Price Target — Prediction for 2027 - TradingView
GRI Bio Inc. (GRI) Rallies 3.8% as Momentum Builds Above Key SupportBollinger Expansion - dars.gov.et
GRI Bio Inc (GRI) Institutional Confidence - TradingKey
GRI Bio Inc (GRI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GRI Bio Secures FDA Orphan Drug Status for IPF - TipRanks
FDA grants Orphan Drug Designation to GRI Bio (NASDAQ: GRI) therapy GRI-0621 in IPF - Stock Titan
GRI Bio receives orphan drug status for IPF treatment - Investing.com
GRI Bio receives FDA orphan drug designation for IPF treatment - grafa.com
GRI Bio receives orphan drug status for IPF treatment By Investing.com - Investing.com Canada
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis - GlobeNewswire
GRI Bio Inc (GRI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GRI Bio Inc (GRI) Valuation: PE, PB & Fair Value Analysis - TradingKey
GRI Bio Inc (GRI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GRIGRI Bio Inc Forecast, Target Price - Finviz
GRI Q1 2026 Earnings: EPS Misses Estimates by 76% Amid Revenue AbsenceEarnings Per Share - lwvtexas.org
GRI Q1 2026 Earnings: Wider-than-expected loss amid ongoing R&D investmentsEarnings Sentiment Score - dars.gov.et
GRI Bio Inc. (GRI) Slips Over 5% as Stock Tests Key Support Near $1.90Median Line - newsline.com
GRI Q1 2026 Earnings: EPS Miss by 76% as Pre-Clinical Biotech Continues to Report No RevenueWeak Earnings Momentum - newsline.com
GRI Q1 2026 Earnings: Wider-than-Expected Loss as EPS Misses EstimatesLong-Term Guidance - newsline.com
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know - Benzinga
GRI Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin Amid Stepped-Up R&D SpendingROIC Trend Report - newsline.com
GRI Q1 2026 Earnings: Wider-than-Expected Loss as EPS Misses Estimates by 76%Dividend Increase Stocks - newsline.com
GRI Bio Inc. (GRI) Struggles Near Support Amid Mixed Technical SignalsVolume Gap - The Legal Advocate
GRI Bio Inc. (GRI) Posts Modest Gains as Stock Holds Above Key SupportWyckoff Spring - The Legal Advocate
GRI Bio Inc. Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Company Faces HeadwindsEPS Consistency Score - The Legal Advocate
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):